EE528 Analysis of Non-Pharmacological Cost Savings Derived from the Use of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients with HER2-Positive Breast Cancer in Spain
Abstract
Authors
T. Calleja E. Galve-Calvo E. Gómez Agudo J.L. Llaguno M. Martin Rufo I. Arroyo J. Lagunar Ruiz M. Lorés M. Monzón C. Saura